文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

纽约州2017-2019年因慢性疼痛接受医用大麻患者处方阿片类药物剂量变化

Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019.
PubMed 文献 · JAMA Netw Open · 2023-01-03
一句话结论在长期阿片治疗患者中,接受医用大麻超过30天与阿片剂量下降相关,基线剂量越高下降幅度越大。

该队列研究利用纽约州处方监测计划2017-2019年数据,纳入8165例因慢性疼痛接受医用大麻且同时接受阿片治疗、此前已接受长期阿片治疗的患者,按医用大麻使用时长分为≤30天(非暴露组4124例)和>30天(暴露组4041例),随访8个月。按基线阿片剂量分层(MME<50、50-<90、≥90),暴露组每月MME下降差值分别为-1.52(95%CI -1.67至-1.37)、-3.24(95%CI -3.61至-2.87)、-9.33(95%CI -9.89至-8.77)。随访最后一个月,暴露组每日MME较基线分别下降48%、47%、51%,非暴露组仅下降4%、9%、14%。作者认为较长时间医用大麻与阿片剂量下降相关,可能降低阿片相关疾病和死亡风险。

要点

  • 在长期阿片治疗患者中,接受医用大麻超过30天者随访8个月内阿片剂量下降幅度大于≤30天者,且基线剂量越高下降越多。
  • 每月MME下降差值:基线MME<50组-1.52(95%CI -1.67至-1.37),50-<90组-3.24(95%CI -3.61至-2.87),≥90组-9.33(95%CI -9.89至-8.77)。
  • 随访最后一个月每日MME较基线下降:暴露组48%、47%、51%,非暴露组仅4%、9%、14%。
  • 暴露组与非暴露组基线中位MME:最低层均为30.0(20.0-40.0),中间层60.0(60.0-70.0)vs 60.0(60.0-90.0),最高层150.0(100.0-216.2)vs 135.0(100.0-218.0)。

适用人群与场景

  • 纽约州处方监测计划2017-2019年数据中,因慢性疼痛接受医用大麻且同时接受阿片治疗、此前已接受长期阿片治疗的患者。
  • 研究随访8个月,从开始医用大麻后观察。

诊断标准与关键阈值

  • 按接受医用大麻时长分组:非暴露组≤30天,暴露组>30天。
  • 按基线阿片剂量分层:MME<50、MME 50至<90、MME≥90。

研究设计与关键结果

  • 研究类型:队列研究,样本量8165例,暴露组4041例(中位年龄57岁,IQR 47-65;女性2376例,58.8%),非暴露组4124例(中位年龄54岁,IQR 44-62;女性2370例,57.5%)。
  • 主要终点:每月MME下降差值(暴露组 vs 非暴露组),基线MME<50组-1.52(95%CI -1.67至-1.37),50-<90组-3.24(95%CI -3.61至-2.87),≥90组-9.33(95%CI -9.89至-8.77)。
  • 随访最后一个月每日MME较基线下降:暴露组最低层48%、中间层47%、最高层51%;非暴露组最低层4%、中间层9%、最高层14%。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在长期阿片治疗患者中,较长时间接受医用大麻与阿片剂量下降相关,可能降低阿片相关疾病和死亡风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with chronic pain often receive long-term opioid therapy (LOT), which places them at risk of opioid use disorder and overdose. This presents the need for alternative or companion treatments; however, few studies on the association of medical cannabis (MC) with reducing opioid dosages exist.

OBJECTIVE: To assess changes in opioid dosages among patients receiving MC for longer duration compared with shorter duration.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study of New York State Prescription Monitoring Program data from 2017 to 2019 included patients receiving MC for chronic pain while also receiving opioid treatment. Of these, patients receiving LOT prior to receiving MC were selected. Individuals were studied for 8 months after starting MC. Data were analyzed from November 2021 to February 2022.

EXPOSURES: Selected patients were divided into 2 groups based on the duration of receiving MC: the nonexposure group received MC for 30 days or fewer, and the exposure group received MC for more than 30 days.

MAIN OUTCOMES AND MEASURES: The main outcome was opioid dosage, measured by mean daily morphine milligram equivalent (MME). Analyses were conducted for 3 strata by opioid dosage prior to receiving MC: MME less than 50, MME of 50 to less than 90, and MME of 90 or greater.

RESULTS: A total of 8165 patients were included, with 4041 (median [IQR] age, 57 [47-65] years; 2376 [58.8%] female) in the exposure group and 4124 (median [IQR] age, 54 (44-62) years; 2370 [57.5%] female) in the nonexposure group. Median (IQR) baseline MMEs for the exposure vs nonexposure groups were 30.0 (20.0-40.0) vs 30.0 (20.0-40.0) in the lowest stratum, 60.0 (60.0-70.0) vs 60.0 (60.0-90.0) in the middle stratum, and 150.0 (100.0-216.2) vs 135.0 (100.0-218.0) in the highest stratum. During follow-up, significantly greater reductions in opioid dosage were observed among the exposure group. A dose-response association of patients' opioid dosage at baseline was observed with the differences in the monthly MME reductions between exposure and nonexposure groups, with a difference of -1.52 (95% CI, -1.67 to -1.37) MME for the lowest stratum, -3.24 (95% CI, -3.61 to -2.87) MME for the middle stratum, and -9.33 (95% CI, -9.89 to -8.77) MME for the highest stratum. The daily MME for the last month of the follow-up period among patients receiving longer MC was reduced by 48% in the lowest stratum, 47% in the middle stratum, and 51% in the highest stratum compared with the baseline dosages. Among individuals in the nonexposure group, daily MME was reduced by only 4% in the lowest stratum, 9% in the middle stratum, and 14% in the highest stratum.

CONCLUSIONS AND RELEVANCE: In this cohort study of patients receiving LOT, receiving MC for a longer duration was associated with reductions in opioid dosages, which may lower their risk of opioid-related morbidity and mortality.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Nguyen T, Li Y, Greene D, et al. Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019. JAMA Netw Open. 2023. PMID: 36716026. doi:10.1001/jamanetworkopen.2022.54573

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。